Discover and read the best of Twitter Threads about #ASCO2022

Most recents (4)

Time and again, doctors and nurses and first responders were given a choice between you and me my human friends. And they chose me. They chose me. Artists too, actors and writers, those who tell stories that in their way also save lives. (1/)
Faced with a choice between returning to “normal” or protecting their patients, their audiences, those whose lives they’ve touched, more of them than not chose normal. More of them than not chose me. (2/)
From countless medical conferences in every medical specialty imaginable (#asco2022 #saem22 #ddw2022 #cdic2022 #EFORT2022 #ILC2022 #Fens2022 #chest22 #NASPGHAN22 and so many more) … (3/)
Read 12 tweets
A thread of my #ASCO22 #ASCO2022 videos for @Plenary_Session

I aim to be educational & what discussant should have said

Suggestions accepted in replies

#1 SHINE - I-BR vs BR, Mantle Cell PFS
#2 DYNAMIC - CT DNA guided Adjuvant CRC
Non-inferiority margin 8.5%!!
CT DNA in Stage II
Oxaliplatin vs 5 FU
Guarantee you will learn something from this video 👇👇
No OS gain
QoL not better
Should we recommend transplant in CR1?
Read 4 tweets
Theres a lot of talk about "top 5 or top 10" abstract lists at #asco2022 and a lot of hype.

In this 🧵, I highlight 5 flawed myeloma studies. I mean no offense to the well intentioned investigators, but do this to encourage critical inquiry and debate.

Read on.

KRD maint vs len maint post auto

Those that were MRD positive paid the "MRD tax" in a big way- 36 months of coming to the infusion center twice a week.

With an endpoint of PFS and comparison of 3 vs 1, result guaranteed.

Wonder what QOL was in K arm?
Dara-RVD for smoldering.


What does "MRD' negativity even mean in someone with smoldering myeloma? Why should the results of this trial matter any more than the dozens of other duplicative small trials? How can you cure some people who WERE NOT gonna progress?
Read 7 tweets
#TumorBoardTuesday #ASCO2022

📢@ASCO is only a few days away & we really wanted to put out our top abstracts to👀for

🙏note - we viewed several thousand titles - so we definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀
#TumorBoardTuesday #ASCO2022
✅Dr. Jones👨‍🏫the Ph2 FAKTION trial of fulv/capi vs fulv/placebo for Breast Ca
➡️Capi⬆️mOS by 6 mos
➡️This⬆️jumped to 19 ms if the tumor harbored PIK3CA or AKT1 activating OR PTEN inactivating🧬mutations
🔎Breast Ca Oral Abstract # 1005
#TumorBoardTuesday #ASCO2022
✅Dr. Rixe👨‍🏫PhI data4⃣OBT076, an ADC🎯the CD205/Ly75 Ag - a receptor⬆️on immunosuppressive dendritic cells
➡️1⃣PR & 6⃣SD out of 2⃣0⃣pts
➡️Near CR in 2⃣pts who then had pembro
🤔Why wasn't☝️more than a poster❓
🔎Abs 3028, Poster 20
Read 32 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!